Oblita
  • About us
    • Who we are
    • Our focus
    • Our motivation
    • How we work
    • Contact us
  • Team
    • Leadership Team
    • Scientific Advisory Board
    • Board of Directors
  • Product
    • D121
  • Global Health
    • Commitment
    • Priority Review Voucher
    • Canine Leishmaniasis
    • Leishmaniasis in humans
    • Chagas Disease
    • Invasive fungal infections
    • Cryptosporidiosis
  • Investors
  • News
Select Page

BREAKING NEWS: A potential new oral drug for leishmaniasis hassuccessfully been tested in healthy humans

Full article EN (.pdf)
Full article FR (.pdf)
Full article DE (.pdf)
Full article SP (.pdf)
Full article NL (.pdf)

© Oblita Therapeutics – global health research & development

TT4CL

  • Follow
  • Follow